Theralase Provides Update on Bladder Cancer Study
Theralase Technologies has announced new patient enrollment for their Phase II clinical study on non-muscle invasive bladder cancer (NMIBC) at the McGill University Health Centre. To date, 12 patients have been treated, with 25% achieving complete response and 25% showing partial response. The company is advancing discussions to open five additional clinical sites in the U.S. and has resubmitted their Fast Track Approval application to the FDA after an initial denial. The study aims to enroll approximately 100 patients and evaluate efficacy, safety, and duration of treatment responses.
- Successful recommencement of patient enrollment and treatment in Phase II NMIBC clinical study.
- 25% of treated patients have achieved complete response, indicating potential efficacy of the treatment.
- Plans to expand the study to five additional U.S.-based clinical sites.
- FDA initially denied Fast Track Approval application, requiring improvements.
TORONTO, ON / ACCESSWIRE / September 24, 2020 / Theralase® Technologies Inc. ("Theralase" or "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and associated drug formulations, announced today that McGill University Health Centre ("MUHC") has re-commenced new patient enrollment and treatment in the Company's Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study ("Study II").
Study II has enrolled and treated 12 patients to date. Out of the 7 patients that are eligible to receive the second treatment, 5 have been treated and 2 are pending. 2 out of the last 5 patients treated for the second time have been treated with the optimized Study II treatment, which will also be the case for the 2 patients that are pending their second treatment.
Efficacy to date at the 90 day assessment includes:
- 3 out of 12 patients (
25% ) have demonstrated a Complete Response ("CR") (Negative cystoscopy and negative (including atypical) urine cytology - 3 out of 12 patients (
25% ) have demonstrated a Partial Response ("PR") (2 patients with negative cystoscopy and positive urine cytology and 1 patient with positive cystoscopy and negative urine cytology), with 2 of these patients having received second treatment.
The Company is in advanced discussions with the US based Trial Management Organization to potentially launch 5 clinical study sites in the United States in 4Q2020, subject to the US economy successfully recovering from the COVID-19 pandemic. If launched in 4Q2020, the Company would expect Study II patient enrollment and treatment in 1Q2021.
Theralase® recently submitted an application to the Food and Drug Administration ("FDA") for Fast Track Approval ("FTA"). The application was denied by the FDA, citing certain improvements required to the application. Theralase has revised the FTA application and has resubmitted it to the FDA. Subject to successful FDA approval of the FTA application, Theralase should be in a position to receive FDA FTA approval in 4Q2020.
Shawn Shirazi, Ph.D., Chief Executive Officer of Theralase stated, "Theralase is pleased that all four Canadian clinical study sites are open for new patient enrollment and we are gearing up to launch 5 additional clinical study sites in the US. We are now able to focus on achieving our interim milestone of treating 20 to 25 patients that could support a Breakthrough Designation application to the FDA. The clinical data collected on the first twelve patients treated shows a favorable clinical response after a single PDT treatment, which the Company expects will improve due to the implemented Study II treatment optimization."
About Study II
Study II utilizes the Therapeutic Dose (0.70 mg/cm2) of TLD-1433 and is focused on the enrollment and treatment of approximately 100 Bacillus Calmete Guérin ("BCG")-Unresponsive NMIBC patients presenting with Carcinoma In-Situ ("CIS") in up to 20 clinical study sites located in Canada and the US.
Study II has a:
- Primary endpoint of efficacy (defined by CR at any point in time
- Secondary endpoint of duration of CR at 360 days post-initial CR (approximately 450 days post initial Study treatment, assuming CR is achieved at the 90 day assessment)
- Tertiary endpoint of safety measured by incidence and severity of Adverse Events ("AEs") grade 4 or higher that do not resolve within 450 days post-initial treatment
The FDA, in its 2018 guidance to industry has stated that, "For single-arm trials of patients with BCG-unresponsive disease, the FDA defines a CR as at least one of the following:
- Negative cystoscopy and negative (including atypical) urine cytology
- Positive cystoscopy with biopsy-proven benign or low-grade NMIBC and negative cytology
- For intravesical therapies without systemic toxicity, the FDA includes, in the definition of a CR, negative cystoscopy with malignant urine cytology, if cancer is found in the upper tract or prostatic urethra and random bladder biopsies are negative.
Intravesical instillation does not deliver the investigational drug to the upper tract or prostatic urethra; therefore, the development of disease in these areas cannot be attributed to a lack of activity of the investigational drug. Thus, sponsors can consider patients with new malignant lesions of the upper tract or prostatic urethra, who have received intravesical therapy to have achieved a CR in the primary analysis; however, sponsors should record these lesions and conduct sensitivity analyses in which these patients are not considered to have achieved a CR."1
About Theralase® Technologies Inc.
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers.
Additional information is available at www.theralase.com and www.sedar.com
Forward Looking Statement:
This news release contains "forward-looking statements" which reflect the current expectations of Company's management for future growth, results of operations, performance, business prospects and opportunities. Such statements include, but are not limited to, statements regarding the Company's proposed development plans with respect to Photo Dynamic Compounds and their drug formulations. Wherever possible, words such as "may", "would", "could", "should", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions; including, with respect to the ability of the Company to: adequately fund, secure the requisite regulatory approvals to commence and successfully complete a Phase II NMIBC clinical study in a timely fashion and implement its commercialization plans. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
1.866.THE.LASE (843-5273)
416-699-LASE (5273)
www.theralase.com
Kristina Hachey
Chief Financial Officer
khachey@theralase.com
416-699-LASE (5273) x 224
1 "BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment - Guidance for Industry" Dated: February 2018
SOURCE: Theralase® Technologies Inc.
View source version on accesswire.com:
https://www.accesswire.com/607534/Theralase-Provides-Update-on-Bladder-Cancer-Study
FAQ
What is the latest update from Theralase regarding their NMIBC clinical study?
What percentage of patients have shown a complete response in the Theralase study?
What are Theralase's plans for expanding their clinical study?
What happened with Theralase's Fast Track Approval application?
What is the primary endpoint of Theralase's Study II?
